Abstract
The precision of genome sequences, together with advanced computational approaches, allows complex, clinically relevant biological systems to be examined. Here, I describe the experiences of the Genome Institute of Singapore (GIS) in using genome-to-systems strategies to accelerate biomedical research. To maximize clinically relevant output, we have explored an organizational strategy that encourages coordinated experimentation among investigators with diverse skills and interests through building a culture of integrative science. Our experience suggests that systems biomedicine is a real and potentially fruitful strategy for translational research.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
A Bayesian analysis of the chromosome architecture of human disorders by integrating reductionist data
Scientific Reports Open Access 20 July 2012
Access options
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Liu, E. T. Systems biology, integrative biology, predictive biology. Cell 121, 505–506 (2005).
Kho, P. S. et al. p53-regulated transcriptional program associated with genotoxic stress-induced apoptosis. J. Biol. Chem. 279, 21183–21192 (2004).
Miller, L. D. et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects and patient survival. Proc. Natl Acad. Sci. USA 102, 13550–13555 (2005).
Berry, D. A. et al. HER-2/neu and p53 expression vs. tamoxifen resistance in estrogen-receptor-positive node-positive breast cancer. J. Clin. Oncol. 18, 3471–3479 (2000).
Bunz, F. et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J. Clin. Invest. 104, 263–269 (1999).
Tan, J. et al. Pharmacologic modulation of glycogen synthase kinase-3beta promotes p53-dependent apoptosis through a direct Bax-mediated mitochondrial pathway in colorectal cancer cells. Cancer Res. 65, 9012–9020 (2005).
Vassilev, L. T. MDM2 inhibitors for cancer therapy. Trends Mol. Med. 13, 23–31 (2007).
Wei, C. L. et al. A global mapping of p53 transcription factor binding sites in the human genome. Cell 124, 207–219 (2006).
Bourque, G. et al. Evolution of the mammalian transcription factor binding repertoire via transposable elements. Genome Res. 18, 1752–1762 (2008).
Zhao, Y. et al. Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. Proc. Natl Acad. Sci. USA 102, 16090–16095 (2005).
Tan, J. et al. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev. 21, 1050–1063 (2007).
Kleer, C. G. et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc. Natl Acad. Sci. USA 100, 11606–11611 (2003).
Varambally, S. et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419, 624–629 (2002).
Jiang, X. et al. DACT3 is an epigenetic regulator of Wnt/β-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications. Cancer Cell 13, 529–541 (2008).
Dhanasekaran, S. M. et al. Delineation of prognostic biomarkers in prostate cancer. Nature 412, 822–826 (2001).
Tomlins, S. A. et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310, 644–648 (2005).
Helgeson, B. E. et al. Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. Cancer Res. 68, 73–80 (2008).
Tomlins, S. A. et al. The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell 13, 519–528 (2008).
Kumar-Sinha, C., Tomlins, S. A. & Chinnaiyan, A. M. Recurrent gene fusions in prostate cancer. Nature Rev. Cancer 8, 497–511 (2008).
Parsons, R. et al. Hypermutability and mismatch repair deficiency in RER+ tumor cells. Cell 75, 1227–1236 (1993).
Markowitz, S. et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 268, 1336–1338 (1995).
Riggins, G. J., Kinzler, K. W., Vogelstein, B. & Thiagalingam, S. Frequency of Smad gene mutations in human cancers. Cancer Res. 57, 2578–2580 (1997).
Wang, Z. et al. Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science 304, 1164–1166 (2004).
Sjöblom, T. et al. The consensus coding sequences of human breast and colorectal cancers. Science 314, 268–274 (2006).
Wood, L. D. et al.The genomic landscapes of human breast and colorectal cancers. Science 318, 1108–1113 (2007).
Acknowledgements
The author wishes to acknowledge the crucial reading of this manuscript by Q. Yu, and the funding support of the Agency for Science and Technology of Singapore.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
Edison T. Liu is on the scientific advisory board of the Eli Lilly Singapore Center for Drug Discovery.
Related links
Rights and permissions
About this article
Cite this article
Liu, E. Integrative biology — a strategy for systems biomedicine. Nat Rev Genet 10, 64–68 (2009). https://doi.org/10.1038/nrg2488
Issue Date:
DOI: https://doi.org/10.1038/nrg2488
This article is cited by
-
A Bayesian analysis of the chromosome architecture of human disorders by integrating reductionist data
Scientific Reports (2012)
